OTCMKTS:PHMMF Pharma Mar (PHMMF) Stock Price, News & Analysis → Bill Gates is all about this tiny $2 stock (From Timothy Sykes) (Ad) Free PHMMF Stock Alerts $31.15 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share Today's Range$31.15▼$31.1550-Day Range$26.85▼$32.5052-Week Range$26.85▼$46.26Volume25 shsAverage Volume99 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Pharma Mar alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Pharma Mar Stock (OTCMKTS:PHMMF)Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.Read More PHMMF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHMMF Stock News HeadlinesMay 18 at 10:29 AM | markets.businessinsider.comRevolutionizing Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMay 16, 2024 | msn.comTransforming Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMarch 18, 2024 | markets.businessinsider.comPharming Group’s Strong Performance and Growth Prospects Justify Buy RatingMarch 16, 2024 | newsweek.comMar-a-lagoMarch 7, 2024 | markets.businessinsider.comPersica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back painFebruary 17, 2024 | investing.comPharma Mar SAU (PHMR)February 1, 2024 | investorplace.comPfizer’s 2024 Comeback: A Dividend Gem in the Pharma MarketJanuary 9, 2024 | msn.comTwo new databases combine computer science and pharmaceutical researchNovember 29, 2023 | msn.comFirst West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In NigeriaNovember 6, 2023 | morningstar.comPharma Mar SA PHMOctober 28, 2023 | markets.businessinsider.comPiramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024July 15, 2023 | barrons.comPharma Mar S.A.June 21, 2023 | forbes.comYifan PharmaceuticalJune 6, 2023 | finance.yahoo.comPHM.MC - Pharma Mar, S.A.April 22, 2023 | msn.comNEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy RecommendationMarch 27, 2023 | marketwatch.comPharmaceutical Excipients Market Top Players By 2031March 25, 2023 | news.yahoo.comPharmaceutical company to open in McHenryMarch 24, 2023 | markets.businessinsider.comInnate Pharma (IPHA) Receives a Buy from H.C. WainwrightMarch 16, 2023 | bizjournals.comBig Pharma companies back new startup out of Mass General BrighamNovember 9, 2022 | markets.businessinsider.comPiramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2023October 10, 2022 | yahoo.comEuropean Commission suspects pharma group Teva broke antitrust rulesAugust 30, 2022 | apnews.comPharmacists Database List of Emails, Phone Numbers, Contact InformationJanuary 11, 2022 | finance.yahoo.comLife Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variantsNovember 11, 2021 | finanznachrichten.dePharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in TaiwanOctober 28, 2021 | news.yahoo.comSpain's PharmaMar posts 58% drop in 9-mth profit despite higher revenuesSee More Headlines Receive PHMMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:PHMMF Previous SymbolNASDAQ:PHMMF CUSIPN/A CIKN/A Webwww.pharmamar.com Phone(491) 846-6000Fax34-91-846-6001Employees509Year Founded1986Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.13 Current Ratio3.01 Quick Ratio2.61 Sales & Book Value Annual Sales$171.15 million Price / SalesN/A Cash Flow$3.23 per share Price / Cash Flow9.63 Book Value$13.04 per share Price / Book2.39Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.16 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Jose Maria Fernandez Sousa-Faro Ph.D.Founder, Executive Chairman, CEO & PresidentMr. Pedro Francisco Fernandez PuentesExecutive DirectorMr. Juan Carlos-Torres Carretero (Age 75)Founder Ms. María Luisa de Francia CaballeroChief Financial OfficerMr. José Luis Moreno Martinez-LosaDirector of Capital Markets & Investor RelationsMr. Juan Gomez PulidoGeneral Counsel & Secretary of the Board of DirectorsMs. Sandra Llamera SanchezGlobal Compliance HeadMs. Lara VadilloCommunication DirectorMs. Belén Sopesén Veramendi Ph.D.Director of Corporate DevelopmentMr. Luis Rupérez CuencaDirector of Human Resources & ITMore ExecutivesKey CompetitorsAmplifonOTCMKTS:AMFPFbioMérieuxOTCMKTS:BMXMFDiaSorinOTCMKTS:DSRLFMDxHealthNASDAQ:MDXHRecordati Industria Chimica e FarmaceuticaOTCMKTS:RCDTFView All Competitors PHMMF Stock Analysis - Frequently Asked Questions How have PHMMF shares performed in 2024? Pharma Mar's stock was trading at $46.26 at the start of the year. Since then, PHMMF stock has decreased by 32.7% and is now trading at $31.15. View the best growth stocks for 2024 here. How do I buy shares of Pharma Mar? Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PHMMF) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma Mar, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.